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SUMMARY 
Gold nanoparticles can serve as an ideal radiosensitizer for radiation therapy due 
to the high-atomic-number nature of gold and the increased tumor specificity in 
nanoparticle form. The degree of radiosensitization is highly dependent on both the local 
gold nanoparticle concentration in the tumor and the radiation source type.  Previous 
Monte Carlo simulations have demonstrated that the gamma-ray energy spectrum of 
Ytterbium-169 is a strong candidate for a high dose rate brachytherapy implementation of 
gold nanoparticle-aided radiation therapy. Therefore, the current study focuses on the 
design of a high dose rate Ytterbium-169 source that would maximize dose enhancement 
during gold nanoparticle-aided radiation therapy; while meeting the practical constraints 
for the production of a clinically relevant brachytherapy source. Different encapsulation 
materials are studied in order to determine its effect on the dosimetric characteristics of 
the source. Specifically, the photon spectra, secondary electron spectra, and dose 
enhancement characteristics are calculated via Monte Carlo simulations to elucidate the 
effects on potential radiosensitization during gold nanoparticle-aided radiation therapy. 
Furthermore, this project involves a study into the modification of external x-ray beams 
from a Philips RT-250 orthovoltage x-ray machine in an attempt to match the dosimetric 
characteristics of the Ytterbium-169 brachytherapy source. This investigation will enable 
the production of an external beam that can serve as a good surrogate of an actual 
brachytherapy source and facilitate the pre-clinical investigation of gold nanoparticle-
aided radiation therapy with Ytterbium-169.  
  




1.1 Gold Nanoparticles in Cancer Therapy 
Radiation therapy remains one of the most effective tools used for battling the 
numerous types of cancers. Radiation therapy techniques vary by radiation type (e.g. 
photons, electrons, protons, or heavy ions), application method (e.g. external beam vs. 
brachytherapy), and energy of the radiation source. Each type of radiation treatment 
has unique advantages and shortcomings that dictate the selection of a specific treatment 
modality and/or technique for a given clinical situation. Regardless of treatment 
modalities and techniques, the ultimate goal of radiation therapy remains the same; to 
maximize the dose delivered to the planning target volume (PTV) while keeping the dose 
to the organs at risk (OAR) at a minimum. This goal has traditionally been accomplished 
through improvements in treatment planning, radiation source equipment, and/or delivery 
techniques (e.g. intensity modulated radiation therapy (IMRT), image guided radiation 
therapy (IGRT), brachytherapy). The recent development of nanomaterials has provided 
an array of new tools with powerful medical applications and consequently given rise to 
nanomedicine, the medical application of such nanomaterials, as an important field of 
clinical research and development. Gold (Au) nanoparticles (GNPs) are one class of 
nanomaterials currently under active investigation for biomedical applications. GNPs can 
be synthesized in a wide variety of shapes (e.g. gold nanospheres, nanorods, nanoshells, 
and nanocages) and possess properties that can be exploited in medicine with powerful 
clinical implications.  
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The unique properties of nanoparticles have made GNPs an attractive choice for a 
wide assortment of medical applications that range from drug delivery [1], cancer 
imaging [2-4], thermal therapy [5-8], and radiation therapy [9-14]. The gold composition 
makes GNPs biologically compatible and allows for conjugation to a variety of 
biomarkers that enables active targeting in solid tumors [3]. Furthermore, as a key 
characteristic of all nanostructures, the small size of GNPs allows for selective 
accumulation in tumors via passive extravasation of GNPs through leaky tumor 
vasculature [15] because the size (1~100 nm) is smaller than the typical cutoff size (~400 
nm) of pores within tumor vasculature [16]. This effect is commonly known as the 
enhanced permeability and retention (EPR) effect [17], and allows for passive targeting 
of tumors. The high-atomic number (Z) of gold (Z=79) and increased tumor specificity of 
GNPs make them an ideal radiosensitizing agent for what is now called gold 
nanoparticle-aided radiation therapy (GNRT). The high-Z of GNPs drastically alters the 
photon interaction probability within tumors, resulting in a clinically meaningful 
enhancement of the dose delivered to tumors. 
1.2 Gold Nanoparticles and Radiation Dose Enhancement 
Dose enhancement due to altered interaction probabilities of tissues was first 
observed in dose measurements during contrast agent imaging studies [18]. Since then, 
multiple efforts of dose enhancement through the use of high-Z materials have been put 
forth, but such efforts have mainly focused on iodine and gadolinium agents during kilo- 
and mega-voltage x-ray irradiation [19-26]. The key physical mechanism that greatly 
enhances the delivered dose with high-Z materials is the increased photoelectron 
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production within the tumor site. This effect comes as a direct result of the relationship 
among photoelectric absorption cross section, the energy of photons, and the atomic 
number of the target as described by:  
                                                          (1.1.1) 
This relationship highlights the prominent increase in photoelectron production with an 
increase in the atomic number or a decrease in the energy of the incident photon. 
Considering the higher atomic number of gold and the greater tumor specificity of gold in 
nanoparticle form, the use of GNPs for the purpose of dose enhancement is expected to 
be far more effective than previous attempts. The efficacy of GNP-mediated dose 
enhancement during radiation therapy was first demonstrated during animal studies using 
250 kVp irradiation [11]. This study showed pronounced tumor regression and increased 
long-term survival for mice treated with GNPs as compared to those treated without. 
Furthermore, the rationale for GNRT has also been demonstrated to be more effective at 
treating radio-resistant tumors such as squamous cell carcinoma in mice [10].  
The dose enhancement due to GNRT has also been quantified by numerous 
Monte Carlo (MC) studies [12-14, 27], showing that the dose enhancement 
characteristics of GNRT are not only dependent on the gold concentration within tumors, 
but also heavily dependent on photon beam quality. These studies conclude that dose 
enhancement may exceed several hundred percent for lower energy radiation sources 
(e.g. keV range photons). The dose enhancement due to the presence of GNPs is a direct 
result of the pronounced increase of photoelectric absorption in the tumor as specified by 
equation 1.1.1. Consequently, the increase in photoelectric absorption leads to an increase 
of up to two orders of magnitude in the number of photoelectrons and Auger/Coster-
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Kronig electrons produced [13]. The extent of this increase and the subsequent dose 
enhancement is directly related to the energy spectrum of the photon source. Therefore, 
in order to maximize the dose enhancement effect of GNRT, the photon source spectrum 
and source design must be chosen carefully. Low-to-intermediate energy brachytherapy 
sources such as Palladium (Pd)-103, Iodine (I)-125, Ytterbium (Yb)-169, and Iridium 
(Ir)-192 are regarded as suitable sources for GNRT as such sources primarily produce 
photons in the keV range. Previous MC studies [13, 14] have investigated the dosimetric 
characteristics of each source type and demonstrated that a high-dose rate (HDR) Yb-169 
brachytherapy source would be the best suited for GNRT. The intensity-weighted average 
energy of a bare Yb-169 source is about ~93 keV, just above the K-edge of gold but 
much lower than other HDR sources such as Ir-192 (~395 keV). Moreover, low-dose rate 
sources such as I-125 or Pd-103 would require multiple injections of GNPs or a sustained 
release of GNPs to induce the desired level of dose enhancement [13, 28], which makes 
the approach impractical for clinical translation.  
1.3 Ytterbium-169  
Yb-169 is produced in a nuclear reactor by neutron activation of Yb-168 in 
ytterbium oxide (Yb2O3) powder via Yb-168(n,γ)Yb-169, and decays with a half-life of 
32 days by electron capture to stable thulium (Tm)-169.  Yb-168 has a natural abundance 
of just 0.13 %, but the high thermal neutron capture cross-section and its availability in 
enriched form (≳ 20 %) allow for very high specific activity of up to 10 Ci/mm3[29-31]. 
As a result, Yb-169 is appropriate for HDR brachytherapy applications and various 
designs of Yb-169 sources have been described in the published literature [29-39]. The 
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relatively low energy photon spectrum of Yb-169 is not only attractive for dose 
enhancement during GNRT, but would also add multiple advantages including the 
possibility of in-vivo shielding of essential organs and tissues, reduced radiation exposure 
to personnel, simplified HDR room shielding, streamlined after-loading units, and overall 
reduced costs [29-34, 37, 39]. Nevertheless, an Yb-169 brachytherapy source is neither 
commercially available in North America at the time nor has its design been carefully 
studied for the purpose of GNRT. Therefore, the current studies are aimed at the design 
of an Yb-169 source that would maximize the dose enhancement during GNRT while 
also meeting practical constraints for manufacturing a clinically-relevant brachytherapy 
source. 
1.4 Overview of the Research 
The research presented herein is based on various tasks aimed at the design and 
pre-clinical study of an Yb-169 brachytherapy source that would maximize dose 
enhancement during GNRT. The design must meet the practical constraints for producing 
a brachytherapy source appropriate for clinical translation while simultaneously being 
optimized for GNRT. The first task involves the encapsulation design of the Yb-169 
source to ensure that the low energy portion of the photon spectrum is preserved for 
maximal dose enhancement. The designs are evaluated based on MC simulations of the 
resulting photon spectra, secondary electron spectra, and dose enhancement 
characteristics. The second task consists of the characterization of the optimized 
brachytherapy source via MC techniques to compute the American Association of 
Physicists in Medicine (AAPM) Task Group (TG)-43 dosimetric parameters: anisotropy 
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function, radial dose function, air kerma strength, and dose rate constant. The third task is 
to develop an MC model to modify a Phillips RT-250 orthovoltage x-ray beam to emulate 
the dosimetric characteristics of the Yb-169 brachytherapy source. The modified beam is 
to be evaluated using the resulting photon spectra, secondary electron spectra, and dose 
enhancement characteristics. The fourth task consists of validating the MC model of the 
Phillips RT-250 machine by comparing MC results with measured photon spectra and 
percent depth dose (PDD). The combination of these tasks will provide a thorough 
characterization of an HDR Yb-169 brachytherapy source optimized for GNRT, as well 
as a modified orthovoltage beam to emulate the Yb-169 source that can facilitate the pre-
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CHAPTER 2 
YTTERBIUM-169 SOURCE ENCAPSULATION DESIGN 
2.1 Yb-169 Source Design 
This investigation was conducted using a number of variations of an Yb-169 
brachytherapy source design. The basic source design was modeled after a commercially 
available HDR Ir-192 source as used in previous studies [12, 40] and similar to that of an 
existing HDR Yb-169 source [37, 41, 42]. The source geometry was designed with an 
active source length of 3.5 mm, a diameter of 0.6 mm, and four different encapsulation 
designs as shown in Figure 2.1.1. The first three designs were all single capsule designs 
with three different capsule materials in alloy form: 6061 aluminum, Ti-6Al-4V (grade 5) 
titanium, and 304 stainless steel. The last design was a dual-capsule design with an inner 
aluminum capsule and an outer titanium capsule similar to that of an Yb-169 source 
developed for industrial applications [43]. The inner aluminum capsule allows for proper 
and safe encapsulation of Yb2O3 during neutron activation. The irradiated aluminum 
capsules containing the neutron-activated source can then be sealed in an outer titanium 
capsule to ensure a higher degree of safety and better means by which to attach to the 
source holder [44]. It should be noted that the aluminum encapsulation design is not a 
clinically relevant design because aluminum is not biocompatible and lacks the required 
strength to safely encapsulate the radioactive core; nevertheless this design was included 
to benchmark the characteristics of an idealized source encapsulation model in terms of 
photon transmission and filtration. 
  




Figure 2.1.1 Yb-169 source geometries for MCNP simulations. LEFT: Single 
encapsulation geometry with capsule made of 6061 aluminum, Ti-6Al-4V titanium or 
304 stainless steel. RIGHT: Double encapsulation geometry with inner 6061 aluminum 
capsule and external Ti-6Al-4V titanium capsule. This model adds a 0.025 cm  thick 
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2.2 Monte Carlo Model 
In order to appropriately discriminate between source designs for GNRT, MC 
simulations were completed to determine changes to the gamma-ray energy spectrum of 
the bare source caused by the encapsulation design. The macroscopic dose enhancement 
factor (MDEF), defined as the ratio of the average dose in the tissue/tumor region with 
and without the presence of GNPs, is also used as an added tool to evaluate each source 
design.  
 
Figure 2.2.1  MCNP geometry which consists of the brachytherapy source centered on a 
30 cm spherical phantom. The tumor region is defined as a 3.5 cm-radius sphere centered 
on the larger phantom. Concentric square (0.1 cm × 0.1 cm) annuli serve as tally regions 
to compute the radial dose distribution along the transverse plane of the source. 
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The phantom geometry and material composition are similar to those used in 
previous studies [12, 13] and represent the typical geometry used for MC characterization 
of brachytherapy sources (Figure 2.2.1). The geometry consists of a source located at the 
center of a 30 cm in radius spherical phantom. The tumor region for all source designs is 
taken as a 3.5 cm radius sphere centered at the origin of the larger sphere and excluding 
the source region. The source region was centered in the phantom where the geometry 
and material composition matched those specified in Figure 2.1.1. The intricate photon 
spectrum of Yb-169 of 62 gamma rays and 20 x-ray emission lines [45] was simplified as 
shown in Figure 2.2.2,  by only taking into account photons with intensities greater than 
0.1% and ignoring dosimetrically irrelevant gamma rays below 10 keV. The intensity-
weighted average energy of this spectrum is just 92.7 keV.  
Figure 2.2.2 Yb-169 photon energy spectrum histogram from Ref. 45 simplified to 
include only those gamma rays with intensity yields that are greater than 0.01% and 
ignoring all dosimetrically irrelevant gamma rays below 10 keV. 
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The composition of the phantom and tumor was taken as that of four-component 
tissue: 10.1% hydrogen, 11.1% carbon, 2.6% nitrogen, and 76.2% oxygen, as defined by 
the International Commission on Radiation Units and Measurements (ICRU) [46]. The 
GNP-loaded tumors were replaced by the ICRU four-component tissue and GNPs at a 
concentration of 7 mg Au/g of tissue. This concentration was chosen based on previous 
animal studies [11] performed with 1.9 nm-diameter GNPs. The level of GNP-loading 
was not changed during the current work as the study was focused on the dose 
enhancement differences produced by each source design. The density of the GNP-loaded 
tissue was increased to reflect the added mass of the tissue from 1       to 1.007 
     . The GNP-loaded tissues were assumed to contain a uniform distribution of GNPs 
with no physical interface between gold and tissue by applying a uniform mixture model. 
The model approximates a uniform distribution of GNPs with a uniform distribution of 
gold atoms among the atoms of other tissue elements. This approximation is not a 
realistic representation of GNP-loaded tissues but it is deemed practical and reasonable 
for MC estimates in the current comparative study of source encapsulation. 
The MC calculations for all the source designs were performed with the Monte 
Carlo N-Particle Code version 5 (MCNP5) [47]. The default cross-sections of the 
MCNP5 system were used to generate particle interaction cross-sections for the gold-
loaded tissues. Photon-transport was the only mode used for the MCNP5 calculations 
because the effect of electron transport is insignificant for the spectral and dose 
calculations performed in the current study. Photon histories were traced down to 1 keV, 
the default cutoff energy by the MCNP5 code. The radial dose distributions along the 
transverse axis of the source between 1 and 10 cm were collected using concentric annuli 
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(cross-sectional dimensions of 0.1 cm high and 0.1 cm wide) using the MCNP5 energy 
deposition F6 tally. The photon flux on the surface of the active source region (i.e. 
surface of Yb-169 source region) and on the surface of the capsule (i.e. past the 
encapsulation material) was collected using the average surface flux F2 tally as a function 
of photon energy in 0.5 keV bins.       particle histories were simulated, and the 
statistical uncertainty (1σ) was less than 0.1 % for all radial dose tally results. The 
statistical uncertainty was less than 0.1 % for all surface flux tally results for bins with a 
photon yield greater than 0.1 %. The intensity-weighted average energy of each spectrum 
was calculated as: 
     
∑     
 
   
∑   
 
   
 
(2.2.1) 
where    is the energy of the flux tally    for the i
th
 bin computed by MCNP5. Additional 
details about the MC simulation and MCNP5 code can be found elsewhere [40, 47]. 
2.3 Photon Spectra from Various Encapsulation Designs  
The MC results reflect the importance of careful consideration of the source 
design for a brachytherapy implantation of GNRT. The effects of source design can 
substantially alter the gamma-ray energy spectrum from the source and in turn lower the 
efficacy of dose enhancement through GNRT. The spectral variations arise due to the 
differences in effective atomic number and total thickness of the capsule that houses the 
active source region. The original Yb-169 photon spectrum shown in Figure 2.2.1 is 
hardened substantially due to self-absorption within the ytterbium region and 
subsequently through interaction with the capsule material. The original photon spectrum 
of Yb-169 has an intensity-weighted average energy of 92.8 keV with about 80 % of the 
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photons with energies below 100 keV. The MC results show strong spectral hardening 
through photon absorption within the source and capsule material. This is expected as 
photoelectric absorption is the dominant photon interaction mechanism within this energy 
regime for most materials and especially those used in the source design. The photon 
spectrum tallied on the surface of the active source length shows significant spectral 
hardening of 30 % when compared to the spectrum shown in Figure 2.2.1 with an 
average energy of 107.6 keV. This photon spectrum, unfiltered by the encapsulation 
material, is shown in Figure 2.3.1 and is referred to as the “unfiltered spectrum”. This 
photon spectrum can change substantially based on the dimensions of the active core as 
self-absorption hardens the spectrum when the size increases.  
Figure 2.3.1 shows the photon spectra and intensity-weighted average energy for 
each of the different source designs. The spectral characteristics that are important to note 
are not only the spectral hardening, but also the decreased fluence after filtration through 
the encapsulation material. Aluminum, with an atomic number of 13, showed spectral 
hardening of just 1.2 % with an average energy of 108.9 keV and a total transmission of 
32 %. This was the smallest increase in average energy and the largest transmission of all 
the designs tested. This is expected from the aluminum source and demonstrates the 
change spectral characteristics of the source under optimal conditions. The titanium 
capsule showed a spectral hardening of 5.0 % with an average energy of 113.0 keV and a 
total transmission of 29 %. The dual-capsule design of aluminum and titanium showed a 
spectral hardening of 4.4 % with an average energy of 112.3 keV, but the added thickness 
of the dual-capsule design caused the total transmission to be just 16%. The stainless 
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steel design had the strongest spectral hardening of 14 % with a total transmission of 25 
%. 
Figure 2.3.1 Photon spectra comparing absorption through different source filter 
materials. The intensity-weighted average energy of each spectrum before and after being 
filtered by encapsulation material reflects the differences in spectral hardening for each 
design. 
2.4 Macroscopic Dose Enhancement Factors 
The spectral differences of each source design had a direct effect on the radial 
dose profile of the source and subsequently on the dose enhancement characteristics of 
each source design. The MDEFs are shown in Figure 2.4.1 as a function of the radial 
distance from the center of the source along the transverse axis of the source. The 
calculated dose ratios beyond the gold-laden region are not strictly MDEF but simply the 
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ratio of the doses of the cases with and without GNPs; and show the reduction in dose 
beyond the gold-laden region. This dose reduction reached a maximum of 10% for the 
aluminum capsule design.  The results show large dose enhancement within the GNP-
laden region between 0 and 3.5 cm of up to 51.0 % at 1 cm for the aluminum capsule 
design.  The titanium capsule design and the aluminum/titanium dual-capsule design had 
very similar dose enhancement profiles with a maximum of 49.3 % at 1 cm. The stainless 
steel capsule design showed the lowest dose enhancement with a maximum of 45.3 % at 
1 cm.  
 
Figure 2.4.1 The calculated macroscopic dose enhancement factors for various 
encapsulation materials of the Yb-169 source as a function of radial distance along the 
transverse axis of the source. 
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As shown in previous studies [13], MDEFs are found to vary with radial distance 
as the photon spectrum changes accordingly. In the GNP-laden region, the MDEF falls 
off as the spectrum hardens within the tumor region. The high effective atomic number of 
the GNP-laden region results in more pronounced photoelectric absorption interactions 
with the low energy photon component of the spectrum. This means that the spectrum 
hardens substantially in the GNP-laden region and as a result the dose enhancement 
decreases by up to 14.5% from 51.0 % to 43.6 % for the aluminum source design. The 
dose enhancement fall-off is most pronounced for the designs that produce the softer 
photon spectra as spectral hardening would be more pronounced for these spectra; this is 
the case for the aluminum capsule design as compared to the stainless steel design.  At 
depths beyond the GNP-laden region, the opposite effect can be observed but is far less 
pronounced, that is, dose enhancement shows a slight increase as the photon spectrum 
softens through the tissue. This happens because in the ICRU tissue Compton scattering 
is the dominant photon interaction mechanism and the scattered photons result in a softer 
photon spectrum, the opposite effect of what is observed in the GNP-laden tumor region. 
2.5 Correlation between MDEF and Spectral Characteristics of Each Source  
Table 2.5.1 summarizes all the spectral characteristics and the MDEF at 1 cm 
from the source for each source design. It can be observed from the results that as the 
photon spectrum hardens and the intensity-weighted average energy of the spectrum 
increases, the dose enhancement decreases. The importance of the low energy component 
of the photon spectrum is further demonstrated by looking at the number of photons 
below 110 and 50 keV and their relationship with the MDEF at 1 cm. The higher the 
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percentage of low energy photons present in the spectrum, the higher the dose 
enhancement. This is particularly expected between 10 and 110 keV as the total 
interaction cross sections of ICRU tissue loaded with 7 mg of gold per gram show a 
substantial increase in the interaction probability in this range. Figure 2.5.1 shows the 
correlation between MDEF and the percentage of photons between 10 and 110 keV 
present in the spectrum for each source encapsulation design.  
 
Table 2.5.1 Spectral and dose enhancement characteristics of the different Yb-169 
encapsulation designs. The results show direct correlation between MDEF and spectral 
characteristics of each source design. 
 
Capsule 
Material Eavg (keV) 
MDEF at 
1 cm 
No. of photons 
10-110 keV (%) 
No. of photons 
below 50 keV (%) 
No. of photons 
below 100keV (%) 
Aluminum  108.9 1.510 64.0% 2.1% 59.1% 
Aluminum & 
Titanium 
112.3 1.493 61.6% 2.7% 56.3% 
Titanium 113.0 1.493 61.3% 2.0% 56.1% 
Stainless Steel 122.9 1.453 54.8% 1.8% 48.9% 
 
 
The percentage of photons within 10-110 keV for each capsule design were 64.0, 
61.6, 61.3  and 54.8 % for aluminum, aluminum/titanium, titanium and stainless steel 
respectively. The MDEF at 1 cm for each design were 1.510, 1.493, 1.493 and 1.453 
respectively. The plot shown in Figure 2.5.1 illustrates how the two quantities vary with 
each source design and demonstrate a strong correlation between the two quantities.  
The MC results illustrate how the choice of source design for a brachytherapy 
implementation of GNRT needs to be scrutinized. The main incentive behind GNRT is to 
take full advantage of the augmented photoelectric absorption of a GNP-laden tumor 
region. This effect is strongly dependent on low energy photons close to the L-edge (~12-
14 keV) and the K-edge (~81 keV) of gold, and as a result the low energy component 
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within this region (~10-110 keV) needs to be maximized to obtain the highest dose 
enhancement during GNRT. Yb-169 has already been shown to be an excellent candidate 
as a brachytherapy source for GNRT [13] and the current study establishes how the 





Figure 2.5.1 MDEF 1 cm away from the source as a function of source design. The 
percentage of photons between 10 keV and 110 keV are shown in the same graph to 




  19 
 
2.6 Secondary Electron Spectra and Microscopic Dose Enhancement 
The resulting secondary electron spectra for all capsule designs were calculated 
and compared against each other. The condensed history Monte Carlo (MC) code 
EGSnrc [48] and user code DOSXYZnrc [49] were used to calculate the secondary 
electron spectrum for each one of the source encapsulation designs. The EGSnrc code 
was used for this task because the source code was immediately available for 
modification using a previously developed technique [13, 14, 27]. The code was modified 
to output the energy and origin of each electron liberated as a result of a photoelectric, 
Compton, or atomic relaxation events (Auger and Coster-Kronig with no differentiation 
between the two). This technique allows for the calculation of the secondary electron 
spectrum originating from gold atoms and tissue molecules separately in a GNP-laden 
tumor region. The resulting electron spectrum yields the average energy of all electrons 
released within the tumor taking into accounts changes in the photon spectrum through 
each encapsulation design and throughout the phantom. The electron spectra were 
collected using logarithmically spaced bins covering a minimum energy of 0.025 keV up 
to the maximum energy of 310 keV with a minimum bin width of 25 eV. 
The MC simulation geometry closely matched that used in the MDEF simulations 
and consists of a source located at the center of a 30 cm-radius spherical phantom with 
the tumor region taken as a 3.5 cm-radius sphere centered at the origin of the larger 
sphere excluding the source region. The source region was defined as a           
         region centered in the tumor representing the brachytherapy source. The source 
geometry was not modeled in detail and deemed not necessary as it was thoroughly 
modeled using MCNP. The MCNP generated photon spectrum just outside each capsule 
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design was used as the input spectrum for this simulation. The material composition of 
the tumor and phantom was taken as four-component ICRU tissue (i.e. 10.1 % hydrogen, 
11.1 % carbon, 2.6 % nitrogen and 76.2 % oxygen). The spectrum of electrons released 
from gold atoms and tissue elements was computed separately using two independent 
simulations. The GNP-laden tumor was loaded with 7 mg of gold per g of tissue (0.7 % 
by weight) and the density was appropriately increased to 1.007 g/cm
3
. The cross-section 
data used for all simulations were generated using the PEGS4 [50] code included in the 
EGSnrc software package. The electron and photon cutoff energies were chosen as 512 
keV and 1 keV respectively for all simulations and       histories were computed for 
each simulation.  
The resulting electron spectra for the titanium and stainless steel encapsulation are 
shown in Figures 2.6.1 and 2.6.2, respectively. The photoelectron spectra for the 
aluminum and aluminum/titanium dual encapsulation design are shown in Appendix A. 
These figures show the total number of electrons originating from photoelectric 
absorption interactions with and without the presence of gold (The contribution from 
atomic relaxations is not shown). The results show the remarkable increase in 
photoelectron yield across the entire range of energy due to the presence of GNPs in the 
tumor as previously reported in the literature [13, 14, 27]. It should be noted that the 
electron spectrum was also calculated for those electrons produced from Compton 
scattering events but are not shown in the figures shown below.  
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Figure 2.6.1 Spectrum of photoelectrons released in the tumor region for the Ti-6Al-4V 
titanium encapsulation design. The figure shows the spectrum from gold and tissue for 
the tumor loaded with 7 mg Au/g tissue and from tissue only. 
 Figure 2.6.2 Spectrum of photoelectrons released in the tumor region for the 304 
stainless steel encapsulation design. The figure shows the spectrum from gold and tissue 
for the tumor loaded with 7 mg Au/g tissue and from tissue only. 
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Figure 2.6.3 LEFT: Spectrum of photoelectrons released in the tumor region from gold 
and tissue for a tumor loaded with 7 mg Au/g of tissue for the 304 stainless steel and the 
Ti-6Al-4V titanium encapsulation design. RIGHT: Low energy region below 100 keV.  
 
 
A similar pattern of photoelectron production is observed for all encapsulation 
designs, but some key differences can be observed in comparing the spectra for the 
stainless steel design and the titanium design as shown in Figure 2.6.3. In the lower 
energy region of < 50 keV, the titanium capsule design shows increased photoelectron 
yield which leads to superior dose enhancement from gold, consistent with the MCNP 
results. The spectra also show some distinct peaks consistent with the gamma-ray 
spectrum of Yb-169 and those related to the photoelectric absorption edges of gold. For 
the stainless steel encapsulation design, a strong peak around ~7.0 keV is present and 
consistent with fluorescence x-rays originating from the iron and nickel atoms present in 
the 304 stainless steel alloy. A quantitative look at the results is summarized in Table 
2.6.1 highlighting some of the key differences between the encapsulation designs. All 
values listed in the table are normalized per source photon. The aluminum encapsulation 
design shows the highest photoelectron and Auger/Coster-Kronig electron yield and 
consequently the highest total energy deposition in both tissue and gold. This is expected 
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as aluminum represents an idealized situation for source encapsulation with minimal 
attenuation and spectral hardening. The aluminum/titanium dual encapsulation design and 
the single capsule titanium design show very similar photoelectron and Auger/Coster-
Kronig electron yield for tissue and gold. The stainless steel design showed the lowest 
photoelectron yield and consequently the lowest energy deposition. On average, the 
titanium encapsulated source deposits 4.98 keV of energy per source photon in the tumor 
region; this compares to 4.52 keV of energy for the stainless steel encapsulation design. 
 
Table 2.6.1 Total yield of photoelectrons (PE) and Auger/Coster-Kronig electrons (AE) 
and intensity-weighted total energy from gold and tissue for a tumor loaded with 7 mg 
Au/g of tissue for each encapsulation design. Auger/Coster-Kronig electrons are only 
produced in gold. All values listed in the table are normalized per source photon.  
 





















Aluminum 0.0702 2.92 0.0485 1.73 4.65 0.130 0.487 
Aluminum/Titanium 0.0684 2.87 0.0468 1.67 4.54 0.126 0.477 
Titanium 0.0677 2.86 0.0462 1.65 4.51 0.125 0.472 
Stainless Steel 0.0606 2.67 0.0404 1.42 4.09 0.112 0.429 
 
 
The differences in the secondary electron spectrum for each source design have 
direct consequences in the local energy deposition around the gold. In order to study this 
behavior at a smaller scale, the microscopic dose enhancement factor (mDEF) was 
calculated for the titanium and the stainless steel encapsulation designs. These two 
designs were chosen because they are the best candidates for an HDR brachytherapy 
source. The aluminum encapsulation design lacks the biocompatibility and structural 
integrity to encapsulate the source and the added thickness of the dual capsule design 
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weakens the strength of the source with no major gain in dose enhancement as shown in 
Table 2.6.1 and Figure 2.4.1.  
The methodology used to calculate all mDEF values was previously developed by 
Jones, et al. [14] and relies on computing the electron point dose kernel due to the 
secondary electron spectrum using the event-by-event MC code NOREC [51]. This MC 
code calculates electron tracks in water. The method involves the calculation of the 
electron point dose kernel from the secondary electron spectra for gold atoms and tissue 
elements separately. The point dose kernels are obtained by modeling each source of 
secondary electrons as a point source of electrons and computing the dose deposited at 
different radial distances. These point dose kernels are used to compute the dose 
enhancement that results from replacing a single point of tissue with gold; this is 
quantified by the ratio of point dose kernels of gold to tissue and defined as the 
microscopic dose enhancement factor [14, 27]. 
The mDEF for the titanium and stainless steel source encapsulation designs are 
shown in Figure 2.6.4. The values are shown for radial distances between 1 and 100 µm 
with both designs showing a similar pattern of dose enhancement with a peak mDEF 
value at 15 µm. However, the titanium source encapsulation design shows consistent 
improvement of local dose enhancement with improved mDEF across the region between 
1 and 20 µm. The biggest improvement is observed around the peak at 15 µm with the 
titanium design showing an mDEF value of 138 and the stainless steel design showing 
119. These values represent a 16 % improvement in mDEF at 15 µm by replacing the 
stainless steel encapsulation with titanium. The cumulative effect from 1 to 20 µm shows 
a consistent improvement over that whole range. 
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Figure 2.6.4 Microscopic dose enhancement factor (mDEF) for the Ti-6Al-4V titanium 
and 304 stainless steel source encapsulation designs for Yb-169.  
 
2.7 Discussion 
The spectral variations from each design considered in the study arise due to the 
attenuation and scattering of source photons traversing the source core and the 
encapsulation material. Consequently, a low-Z biocompatible material with the structural 
integrity to safely encapsulate the radioactive core of the source is preferred as the 
encapsulation material of any brachytherapy source considered for GNRT.  Overall, the 
following aspects of each source design need to be taken into consideration for an 
optimum Yb-169 source design for GNRT. The aluminum, titanium and 
aluminum/titanium capsule designs resulted in somewhat comparable dose enhancement 
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characteristics but showed different transmission characteristics that would affect the 
strength of each source. Despite its superiority to other encapsulation materials in terms 
of producing an enhancement in dose, aluminum itself is not biocompatible and therefore 
not suitable as an encapsulation material for a brachytherapy source. Furthermore, an 
aluminum capsule lacks mechanical strength and would be susceptible to breakage, 
posing a major safety risk in clinical practice. Stainless steel, on the other hand, is a safe 
and biocompatible material but its use as a source encapsulation material produced the 
smallest amount of dose enhancement in this study. As a result, it is less desirable to 
adopt the stainless steel source design for GNRT. The dual encapsulation design with 
aluminum and titanium provides an adequate strength for the source as well as desirable 
dosimetric characteristics for GNRT and has been demonstrated as a feasible design for 
manufacturing [43]. However, the added filter thickness significantly decreases the 
photon transmission through the capsule, which hinders the production of an HDR 
source. Furthermore, if not manufactured carefully, the added complexity of having two 
layers of encapsulation would also increase the likelihood of geometrical distortions, 
potentially affecting the dosimetric characteristics of the source. 
The titanium capsule design appears to meet the source design goals more 
favorably because it allows for a significant improvement in the dose enhancement 
characteristics when compared to the stainless steel capsule design, while avoiding some 
of the shortcoming of the aluminum and dual encapsulation source designs. Titanium 
provides excellent biocompatibility, high corrosion resistance, and exceptional strength 
for safe encapsulation of the activated Yb core. Moreover, the low density of titanium 
(~4.4 g/cm
3
), about 45% lower than that of stainless steel (~8.0 g/cm
3
), allows good 
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photon transmission through the source capsule, while preserving much of the low energy 
photon component in the Yb-169 spectrum. The added strength of titanium over stainless 
steel [52] also provides the opportunity to decrease the thickness of the capsule and 
potentially further improving the dose enhancement properties of the source.  
The current MC results reflect the importance of careful consideration of the 
source design for a brachytherapy implementation of GNRT. As shown in this study, the 
source encapsulation can substantially alter the photon spectrum from the source and in 
turn affect the amount of dose enhancement achievable under the given irradiation 
scenario. The change in the source photon spectrum affects the dose enhancement not 
only macroscopically but also microscopically on a cellular scale. The results of this 
study consistently show the titanium encapsulation design would produce improved dose 
enhancement and radiosensitization during GNRT. 
The current MC results showed that there were statistically significant variations 
among the investigated source capsule designs, in terms of photon spectrum, transmitted 
photon fluence, macroscopic dose enhancement, and microscopic dose enhancement. 
Specifically, under the identical source and phantom geometry, there was an increase in 
the average photon energy, a decrease in the photon transmission, and a decrease in the 
macroscopic and microscopic dose enhancement, respectively, as the encapsulation 
material changed from aluminum through titanium to stainless steel. Additionally, the 
aluminum/titanium dual capsule design exhibited dosimetric characteristics comparable 
to those associated with the titanium capsule design, except for a slight decrease in the 
photon transmission. In comparison with a more conventional stainless steel capsule 
design, all three other capsule designs considered in this study resulted in a significant 
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improvement (~10%) for the macroscopic and microscopic dose enhancement achievable 
under the given GNRT scenario. The increased structural integrity of titanium over 
stainless steel may also provide the opportunity to shrink the size of the capsule design, 
further improving the dose enhancement characteristics of the source. 
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CHAPTER 3 
TG-43 CHARACTERIZATION OF YTTERBIUM-169 SOURCES 
3.1 TG-43 Formalism for Brachytherapy Dose Calculation 
The dose formalism for brachytherapy sources specified by the AAPM TG-43 
was first presented in 1995. Earlier dose calculation formalisms were only dependent on 
apparent activity (Aapp), exposure-rate constants, tissue-attenuation coefficients, and 
equivalent mass of radium. However, it did not account for differences in source 
geometry and it mainly depended on the type of radionuclide. TG-43 introduced a new 
set of dosimetric parameters that not only depended on the specific geometry of the 
brachytherapy source but could also be directly measured or calculated for each source. 
The new formalism introduced by TG-43 resulted in standardization of dose-calculation 
methods and dose distributions of brachytherapy sources [53]. 
The general formalism is based on the 2D dose-rate equation: 
 ̇           
       
         
              
(3.1.1) 
where r represents the distance (cm) from the point of interest to the center of the active 
source region, ro is the reference distance defined as 1 cm,   is the polar angle that 
defines the point of interest relative to the longitudinal axis of the source, and    defines 
the reference angle at the traverse plane of the source, and specified to be    . As shown 
in Figure 3.1.1 the point          defines the reference point that lies on the traverse 
bisector of the source. The quantities of interest that are needed to completely 
characterize the dose distribution of a brachytherapy sources are:     
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   the air-kerma strength of the source (µGy·m
2
/h)  
  the dose-rate constant in water (1/m2) 
       the geometry function (1/m2) 
      the radial dose function  
       the anisotropy function  
Figure 3.1.1 Geometry and coordinate system used to define the TG-43 dose calculation 
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3.1.1 Air-Kerma Strength 
   is the air-kerma strength of the source and it is a quantity used to describe the 
strength of the source based on the air-kerma rate, at a distance large enough such that the 
source can be considered a point source. The air-kerma rate  ̇ is the sum of kinetic 
energy transferred to electrons and positrons per unit mass in air and time. The 
relationship between air-kerma rate and the air-kerma strength is: 
    ̇      
  (3.1.2) 
where  ̇     is the air-kerma rate in vacuo due to photons of energy greater than  , at a 
distance  . The distance   is the distance from the center of the active source region to a 
point along the traverse plane of the source. This distance should be much larger than the 
greatest linear dimension of the source such that the source is considered a point source 
and typically chosen to be 100 cm. The cutoff energy   excludes any low-energy 
contaminant photons that may contribute to  ̇     without contributing to the dose at any 
distance beyond 1 mm in tissue. This contribution may arise from any characteristic x-ray 
peaks arising from the encapsulation material (e.g. titanium or stainless steel) [53]. 
3.1.2 Dose-Rate Constant 
The dose rate constant   is defined as the dose rate to water at a distance of 1 cm 
on the transverse axis reference point         per unit air-kerma strength: 
  




The dose-rate constant accounts for the effects of source geometry, spatial distribution of 
radioactivity within the source itself, filtration by the source encapsulation, and scattering 
  
  32 
 
in water surrounding the source. This definition now depends on both the radionuclide 
and the specific source geometry.  
3.1.3 Geometry Function 
The geometry function accounts for any geometric fall-off of the fluence with 
distance r and the spatial distribution of radioactivity within the source. The purpose of 
the function is to increase the accuracy in situations in which dose rates are approximated 
by interpolation of tabulated data. The geometry function does not take into account 
attenuation or scattering in the medium and it is an effective inverse square law 
correction. In the case of a line-source geometry like the ones proposed in the current 
work the geometry function is: 
        
 
      
    for      
        
 
   
  
 
     for      
(3.1.4) 
where   is the angle measured in radians subtended by the tips of the source with respect 
to the point of interest        as shown in Figure 3.1.1 and L is the length of the active 
source region. 
3.1.4 Radial Dose Function 
The radial dose function accounts for dose fall-off along the transverse axis due to 
absorption and scatter in tissue. This function complements the definition of the geometry 
function that does not include scattering and attenuation in tissue.  
      
 ̇      
 ̇       
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3.1.5 Anisotropy Function 
The anisotropy function accounts for the anisotropy of the dose distribution 
around the source as a function of the polar angle and defined as: 
       
 ̇     
 ̇      
        
       
 
(3.1.6) 
The anisotropy function is defined as unity on the transverse plane and decreases as r 
increases, as   approaches 0  or 180  and as the photon energy decreases. 
3.2 Monte Carlo Calculation 
Table 3.2.1 Yb-169 photon spectrum including all photons with yields greater than 0.1 % 
and ignoring all dosimetrically irrelevant gamma rays below 5 keV. 
 

















 TOTAL    3.32083 
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The radiation transport code MCNP5 was used to compute all the necessary 
quantities to characterize the Yb-169 source as defined by TG-43. The source and 
encapsulation geometry were modeled exactly as shown in Figure 2.1.1. The active 
region of the source was modeled with a uniform activity distribution. The Yb-169 
photon spectrum used is shown in Table 3.2.1 excluding all photons with intensity lower 
than 0.1 % and energy lower than 5 keV as specified in TG-43 [47]. Two different 
MCNP models were developed to compute all TG-43 parameters.  
 
 
Figure 3.2.1 MCNP tally geometry for computing the air kerma strength at      
  
and         . The source is centered on a spherical region in vacuo with a radius of 
130 cm. 
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The air-kerma strength    was calculated with the Yb-169 source centered on a 
130 cm radius spherical phantom in vacuo. The air-kerma rate was determined at the 
reference point      
  at a distance d = 100 cm using the MCNP5 energy deposition 
F6 tally with units of              . This region was defined by first delineating the 
region at d = 100 cm from the center of the source by defining two concentric spheres 
with radii of 97.5 cm and 102.5 cm. The angular constraint of      
  was defined by 
using two cones with vertex angles of      one aligned with the +z-axis and the other 
aligned with the –z-axis. This defines a 5 cm ring tally centered at d = 100 cm with 
     
     as shown in Figure 3.2.1. The MCNP output is the air-kerma per source 
photon       in units of      
           . The air-kerma rate is calculated from 
    and converted to units of        
       by: 
 ̇                     
 
   
     
 
(3.2.1) 
where    is the total number of photons per disintegration of the source. The air-kerma 
rate may also be written in terms of the unit   (           ) as specified in TG-43 
[53]. 
 The dose distribution surrounding the source was computed by simulating the 
source centered in a spherical water phantom with a radius of 50 cm, an appropriate size 
to approximate full-scatter conditions of a semi-infinite water phantom. An array of tally 
regions was modeled to collect the dose at radial distances of 0.5 cm and 1-10 cm in 1 cm 
steps and at angles between      and         in      steps. This was accomplished 
by generating spherical shells with mean radii at the desired radial distance (i.e. 0.5 cm 
and 1-10 cm in 1 cm steps). The thickness of each shell was calculated to be as thin as 
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possible to appropriately approximate the detection region while maximizing collection 
efficiency during the MC simulation. The criteria were developed by Luxton et al. [54] 
and compares the factor       
    
  ⁄  
 
  that subdivides each shell bounded by the 
inner radius    and outer radius    into smaller shells of equal volume, with the mean 
radius of the shell            ⁄ . The calculated dose for a shell approximates the 
dose at that mean radius of the shell only if the two factors differ by less than 1 %, i.e. 
|     ⁄  
   |      . 
The angular dependence of each tally region was defined by using concentric 
cones about the +z-axis and –z-axis to restrict collection along the desired angle from 
     to        in     steps. For the      region, a cone along the –z-axis with 
vertex angle of    defined the      region; a similar cone along the +z-axis defined the 
      . The regions between     and      are defined by concentric cones centered 
at the desired angle with an angular opening    , e.g. for the       two concentric 
cones centered along the –z-axis with vertex angles of    and     defined the desired 
tally region. The same method was used to define all of the angles and using concentric 
cones with the appropriate vertex angles to define each region in     (i.e.  
                         . The result is a series of ring tallies that collect the dose 
distribution surrounding the source as shown in Figure 3.2.2. 
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Figure 3.2.2 MCNP tally geometry for computing the dose distribution around the Yb-
169 source.  
 
3.3 Results and Discussion 
The dosimetric characterization outlined in TG-43 was completed for the Ti-6Al-
4V titanium source encapsulation design and the 304 stainless steel source encapsulation 
design as these two sources are the best candidates for an HDR brachytherapy source. 
The air-kerma strength calculated by MC resulted in                  
  for the 
Ti-6Al-4V titanium design and                  
  for the 304 stainless steel 
design. The dose rates at the reference point  ̇         were calculated as  ̇        
                        for the Ti-6Al-4V titanium design and  ̇        
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                        for the 304 stainless steel design. The dose-rate constants 
were calculated as                         for both source designs. This value 
compares well to other reported values for Yb-169 source models:               
[31],               [55],             [37]               , and   
                        [56]. 
Table 3.3.1 Calculated geometry function         for both Ti-6Al-4V titanium and 304 
stainless steel source encapsulation designs. 
 
The geometry function         (Table 3.3.1) was equivalent for both designs 
because they shared the exact dimensions within the active source region. The function 
represents the effective inverse-square correction based on the line-source approximation 
outlined in equation 3.1.4. The function shows both sources effectively become point 
sources for         The radial dose functions are shown on Table 3.3.2 and the fit to 5th 
order polynomial as specified in [53] is shown in Figure 3.3.1 and are equivalent for both 
sources. The 2D anisotropy function for the Ti-6Al-4V titanium and the 304 stainless 




0.5 1 2 3 4 5 6 7 8 9 10 
0 4.558 1.032 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
10 4.530 1.030 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
20 4.450 1.026 0.252 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
30 4.337 1.021 0.251 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
40 4.212 1.014 0.251 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
50 4.092 1.006 0.250 0.111 0.063 0.040 0.028 0.020 0.016 0.012 0.010 
60 3.989 1.000 0.250 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010 
70 3.912 0.995 0.250 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010 
80 3.864 0.991 0.249 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010 
90 3.848 0.990 0.249 0.111 0.062 0.040 0.028 0.020 0.016 0.012 0.010 
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Figure 3.3.1 Calculated radial dose function for the Ti-6Al-4V titanium source design 
and 5
th
 degree polynomial fit along with corresponding fitting parameters. 
 
Table 3.3.2 Radial dose function         values for the Ti-6Al-4V titanium and 304 
stainless steel source designs.  
 
r (cm) gL (r ) for Ti design gL (r ) for SS design 
0.5 0.952 ± 0.027 0.956 ± 0.027 
1 1.000 ± 0 1.000 ± 0 
2 1.076 ± 0.030 1.076 ± 0.030 
3 1.127 ± 0.032 1.127 ± 0.032 
4 1.157 ± 0.033 1.157 ± 0.032 
5 1.168 ± 0.033 1.168 ± 0.033 
6 1.165 ± 0.033 1.165 ± 0.033 
7 1.149 ± 0.032 1.149 ± 0.032 
8 1.123 ± 0.032 1.123 ± 0.032 
9 1.090 ± 0.031 1.090 ± 0.031 







ao=0.904     a1=0.108    a2=-0.105 
















0.5 1 2 3 4 5 6 7 8 9 10 
0 0.568 ± 0.018 0.566 ± 0.018 0.618 ± 0.020 0.662 ± 0.021 0.700 ± 0.022 0.729 ± 0.023 0.750 ± 0.024 0.770 ± 0.024 0.786 ± 0.025 0.799 ± 0.025 0.809 ± 0.026 
10 0.630 ± 0.020 0.642 ± 0.020 0.690 ± 0.022 0.727 ± 0.023 0.756 ± 0.024 0.777 ± 0.024 0.795 ± 0.025 0.810 ± 0.025 0.822 ± 0.026 0.832 ± 0.026 0.842 ± 0.026 
20 0.737 ± 0.023 0.746 ± 0.023 0.779 ± 0.024 0.804 ± 0.025 0.823 ± 0.026 0.837 ± 0.026 0.849 ± 0.027 0.859 ± 0.027 0.867 ± 0.027 0.874 ± 0.027 0.880 ± 0.028 
30 0.823 ± 0.026 0.828 ± 0.026 0.848 ± 0.027 0.864 ± 0.027 0.876 ± 0.027 0.886 ± 0.028 0.893 ± 0.028 0.900 ± 0.028 0.905 ± 0.028 0.909 ± 0.029 0.913 ± 0.029 
40 0.887 ± 0.028 0.888 ± 0.028 0.901 ± 0.028 0.911 ± 0.029 0.918 ± 0.029 0.924 ± 0.029 0.929 ± 0.029 0.932 ± 0.029 0.935 ± 0.029 0.938 ± 0.029 0.941 ± 0.029 
50 0.933 ± 0.029 0.933 ± 0.029 0.940 ± 0.029 0.946 ± 0.030 0.950 ± 0.030 0.953 ± 0.030 0.956 ± 0.030 0.958 ± 0.030 0.960 ± 0.030 0.961 ± 0.030 0.963 ± 0.030 
60 0.963 ± 0.030 0.964 ± 0.030 0.968 ± 0.030 0.971 ± 0.030 0.973 ± 0.031 0.975 ± 0.031 0.976 ± 0.031 0.977 ± 0.031 0.978 ± 0.031 0.979 ± 0.031 0.980 ± 0.031 
70 0.983 ± 0.031 0.985 ± 0.031 0.987 ± 0.031 0.988 ± 0.031 0.989 ± 0.031 0.990 ± 0.031 0.990 ± 0.031 0.990 ± 0.031 0.991 ± 0.031 0.991 ± 0.031 0.991 ± 0.030 
80 0.996 ± 0.031 0.995 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.998 ± 0.031 0.998 ± 0.031 0.998 ± 0.031 0.998 ± 0.031 0.998 ± 0.031 0.998 ± 0.031 0.998 ± 0.030 
90 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 1.000 ± 0 





0.5 1 2 3 4 5 6 7 8 9 10 
0 0.570 ± 0.018 0.566 ± 0.018 0.611 ± 0.020 0.653 ± 0.021 0.689 ± 0.022 0.718 ± 0.023 0.738 ± 0.024 0.758 ± 0.024 0.774 ± 0.025 0.788 ± 0.025 0.799 ± 0.026 
10 0.615 ± 0.020 0.621 ± 0.020 0.666 ± 0.022 0.705 ± 0.023 0.734 ± 0.024 0.757 ± 0.024 0.776 ± 0.025 0.791 ± 0.025 0.805 ± 0.026 0.816 ± 0.026 0.827 ± 0.026 
20 0.704 ± 0.023 0.715 ± 0.023 0.750 ± 0.024 0.777 ± 0.025 0.799 ± 0.026 0.815 ± 0.026 0.829 ± 0.027 0.840 ± 0.027 0.849 ± 0.027 0.858 ± 0.027 0.865 ± 0.028 
30 0.793 ± 0.026 0.799 ± 0.026 0.822 ± 0.027 0.841 ± 0.027 0.855 ± 0.027 0.866 ± 0.028 0.876 ± 0.028 0.883 ± 0.028 0.890 ± 0.028 0.896 ± 0.029 0.901 ± 0.029 
40 0.866 ± 0.028 0.866 ± 0.028 0.881 ± 0.028 0.892 ± 0.029 0.902 ± 0.029 0.909 ± 0.029 0.915 ± 0.029 0.920 ± 0.029 0.923 ± 0.029 0.927 ± 0.029 0.931 ± 0.029 
50 0.920 ± 0.029 0.918 ± 0.029 0.927 ± 0.029 0.933 ± 0.030 0.939 ± 0.030 0.943 ± 0.030 0.946 ± 0.030 0.949 ± 0.030 0.951 ± 0.030 0.954 ± 0.030 0.956 ± 0.030 
60 0.957 ± 0.030 0.956 ± 0.030 0.960 ± 0.030 0.964 ± 0.030 0.967 ± 0.031 0.968 ± 0.031 0.970 ± 0.031 0.972 ± 0.031 0.973 ± 0.031 0.974 ± 0.031 0.976 ± 0.031 
70 0.981 ± 0.031 0.981 ± 0.031 0.983 ± 0.031 0.985 ± 0.031 0.986 ± 0.031 0.987 ± 0.031 0.987 ± 0.031 0.988 ± 0.031 0.988 ± 0.031 0.989 ± 0.031 0.990 ± 0.030 
80 0.995 ± 0.031 0.995 ± 0.031 0.996 ± 0.031 0.996 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.997 ± 0.031 0.998 ± 0.030 




The differences in filtration through the titanium encapsulation design are evident 
in the anisotropy function as shown in Figure 3.3.2. The values are reduced through polar 
angles that correspond to going through the most encapsulation material, at which the 
differences in composition are most pronounced. Dosimetric perturbations are more 
pronounced in the 2D anisotropy function for the stainless steel source design due to the 
increased density and attenuation through the stainless steel as opposed to the titanium. 










MONTE CARLO MODEL OF A PHILLIPS RT-250 
ORTHOVOLTAGE MACHINE 
It has been demonstrated [13, 14, 27] that a low-energy photon spectrum such as 
that of an Yb-169 brachytherapy source results in the most favorable change in 
photoelectron yield, and a substantial increase in energy deposition during GNRT. In 
order to demonstrate the feasibility and effectiveness in actual GNRT scenarios, this 
finding needs to be investigated via in-vivo and in-vitro studies. A brachytherapy source 
design such as the one specified in Chapter 2 would be cost-prohibitive for such studies 
because it is currently unavailable from a commercial vendor, and would require 
significant design and manufacturing efforts for custom production. Moreover, the use of 
a brachytherapy source would significantly increase the complexity of the study by 
placing added requirements for adequate source handling and dosimetry. Thus, this part 
of the research is aimed at matching the general dosimetric characteristics of an Yb-169 
source using an external x-ray beam from a Phillips RT-250 orthovoltage x-ray machine. 
This approach substantially reduces the source-related burden during radiobiology studies 
of GNRT with an Yb-169 source. In this study, an MC model of a Phillips RT-250 
orthovoltage machine is developed and validated. A model of this type would allow for 
the study of beam filtration and subsequent modification of the photon spectrum. The 
goal is to obtain a flexible model that allows the freedom to place a filter of any material, 
of any size, at any location and rapidly determine its effects on the photon spectrum and 




4.1 Monte Carlo Model 
The original x-ray beam was studied through the development of an MCNP model 
of the Phillips RT-250 orthovoltage machine. The geometry of the machine housing, 
filtration, and applicators were defined in MCNP as shown in Figure 4.1.1.  The model 
includes the vacuum region, beryllium window, all collimators, and the inherent copper 
filtration. The geometry of all the internal structures of the machine are not available 
from the manufacturer and were deduced from published literature [57] and physical 
measurements for MCNP modeling of the machine head. The bremsstrahlung production 
from the target was not modeled in the interest of computing efficiency. Instead, the 
bremsstrahlung spectrum released from the tungsten target was obtained from the 
software package SpekCalc [58-60], a well-validated x-ray spectrum generator that 
analytically computes the bremsstrahlung spectrum. The calculated x-ray spectrum was 
inserted into the model as a photon point source at the position where the electron beam 
would impact the tungsten target.  
The Phillips RT-250 orthovoltage machine was modeled for the following three 
kilo-voltage beam settings: 75 kVp, 125 kVp, and 250 kVp. The 75 kVp and 125 kVp 
beams are filtered only by the inherent filtration of the machine, while the 250 kVp beam 
is filtered by 0.25 mm Cu as well as the inherent filtration of the machine. Figure 4.1.1 
shows a cross-sectional view and a three-dimensional view of the machine head geometry 














Figure 4.1.1 MCNP geometry for Phillips RT-250 orthovoltage machine model. LEFT: 
Cross-sectional view of machine head model. Geometry includes vacuum region, 
beryllium exit window, copper and lead cone collimators, and square lead collimators. 
RIGHT: Three-dimensional view of the MCNP geometry used for simulation showing 







The photon spectrum for each beam (i.e. 75 kVp, 125 kVp and 250 kVp) was 
calculated using the average flux MCNP F4 tally in air right after all collimation. A 30 x 
30 x 30 cm
3
 water phantom was used to compute the PDD along the central axis of the 
phantom for standards conditions of a 10 cm  10 cm field size at 50 cm SSD. 
Cylindrical cells of 4 cm in diameter were used along the central axis to act as photon 
dose detectors. The height of the each cell was kept at 0.1 cm for the 1 cm region close to 
the surface. The height was increased to 0.2 cm for the rest of the detectors along the 
central axis down to a depth of 20 cm. The MCNP5 energy deposition F6 tally was used 
to obtain the full depth dose data along the central axis. The number of histories used was 
set to 2x10
8
 in order to keep the relative uncertainty of each cell < 0.3%. 
4.2 Experimental Validation of Photon Spectrum  
The MC model was validated by comparing the spectra obtained via MC methods 
with measured x-ray spectra. The measurement of x-ray spectra can be a difficult task 
given the high photon flux of the source and the energy resolution requirements. 
Semiconductor detectors such as cadmium telluride (CdTe), cadmium zinc telluride 
(CdZnTe) and high-purity germanium (HP-Ge) are the preferred detector systems for x-
ray spectrum measurements. HP-Ge detector systems require liquid nitrogen cooling 
systems that are expensive, large, and difficult to work with. CdTe and CdZnTe detector 
systems are capable of operating with a compact thermoelectric cooling system without 
the need of any external cooling. For this work, a CdTe detector system was chosen given 





Figure 4.2.1 Detector geometry for measurements of the incident spectra of the Phillips 
RT-250 orthovoltage machine. 
 
The choice of detection geometry remains another important aspect to consider in 
order to measure the x-ray spectrum properly. The high photon flux of the Phillips RT-
250 orthovoltage source requires heavy collimation and large detector to source distances 
in order to avoid pulse pileup in the detector. These complications are avoided using a 
90
o
 Compton scattering technique [61-64]. The technique requires a scattering medium 
and the measurement of the     photon spectra that scatters off of the medium; this 
scattered spectrum is used to reconstruct the incident spectrum of the source. A low-Z 
scattering medium with no characteristic peaks such as Carbon (C) was chosen as the 
method developed by Maeda et. al. [65]. The detection geometry was arranged as shown 
in Figure 4.2.1 using a                right triangular prism cut out of graphite, a 
common allotrope of C. The detection geometry also included a 2.5 mm-diameter lead 




Figure 4.2.2 X-ray detection system for photon spectra measurements. 
 
The detection system used is based on a pre-amplified and thermoelectrically 
cooled CdTe photodiode detector (AXR CdTe, Amptek Inc.). The detector crystal has a 
surface area of        and 1 mm in thickness with an energy resolution of < 1.5 keV 
at 122 keV (< 1.22 %) for 
57
Co. The signal processing system (Figure 4.2.2) used in 
conjunction with the detector is composed of three major components: 1) a digital pulse 
detector (DP5, Amptek Inc.) that serves as the shaping amplifier and multichannel 
analyzer (MCA) and used in conjunction with the CdTe detector. 2) a detector power  
supply and PC interface board (PC5, Amptek Inc.)  3) a computer with Amptek 
DPPMCA display and acquisition software.  
The collected spectra needs to be corrected for detector response, namely the 
escape of secondary x-rays and absorption efficiency. Each collected spectrum was 
corrected by applying a stripping procedure [65] specified by: 
       
       ∑             
    
        
        
 (4.3.1) 




of scattered photons in energy   ,      is the highest energy detected in the spectrum, 
        is the monoenergetic response function of the detector, and          is the full 
energy absorption efficiency. The process is applied step-wise starting at the maximum 
energy      down to the lowest energy           . 
The monoenergetic response functions and full-energy absorption efficiency for 
the CdTe detector was obtained via MC simulations using MCNP5. The model included 
the CdTe crystal (        ), the top platinum (Pt) contact (0.2 µm), the bottom 
indium (In) contact (1 µm), and the Be window (100 µm). The detector geometry was 
exposed to 1 mm in radius monoenergetic beams of photons from 1 to 250 keV in 0.5 
keV steps. The response function for each monoenergetic beam was calculated using the 
pulse height distribution MCNP F8 tally in the CdTe crystal. A total of 500 independent 
input decks were simulated to compute all of the necessary response functions and the 
full energy absorption peak efficiency as shown in Figure 4.2.3.  





The     photon spectrum corrected for energy response is used to reconstruct the 
incident spectrum via the Klein-Nishina formula. The energy of an incident photon    
scattered by 90
o
 and detected as     is given by: 
   
   




where   is the rest mass of an electron and   is the speed of light in vacuum. The Klein-
Nishina formula yields the differential cross section of photons scattered from a single 
electron per unit solid angle and written as: 
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where   is the atomic number of the scattering medium,   is the classical electron radius, 
    ⁄    
 , and   is the scattering angle. The fraction of photons scattered into 
     is given by: 















   
) (4.3.4)   
Therefore, the incident spectrum        can be reconstructed from the scattered   
  
spectrum        as [65]: 
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The Klein-Nishina formula assumes an unbound and stationary electron in the 
derivation of equation 4.3.3. The drift velocities of electron in the scattering medium 
result in Doppler broadening of the characteristic peaks of the spectrum. This broadening 
can be removed by deconvolution of the characteristic peaks by [64]: 
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(4.3.6)   
where T is the mean kinetic energy per electron in the scattering medium and equal to 
0.2842 keV in carbon [66]. This quantity is deduced from the virial theorem, that states 
that the kinetic energy per electron is approximately equal to the absolute value of the 
biding energy per electron [67]. The deconvolution therefore looks at the first and second 
derivatives of the photon spectrum around each characteristic peak and should only be 
applied around the energy interval directly adjacent to the energy bins corresponding to a 
characteristic peak.  
The     measured spectrum and resulting final reconstructed spectrum are shown 
in Figure 4.2.4 for the 250kVp beam filtered by 0.25 mm Cu. The rest of the measured 
and reconstructed final spectra for 75 kVp, 100 kVp, and 125 kVp are shown in 
Appendix B. Figure 4.2.4 shows the measured spectrum by the detector (red dashed line) 
and the detector response-corrected spectrum (solid blue line). It can be appreciated after 
response correction there is an over-response in the lower energy region of the spectrum, 
and an under-response in the higher energy region as the absorption efficiency of the 
detector decreases. The Compton-corrected spectrum (black square-solid line) 




characteristic peaks are now shown in the correct region for tungsten, namely 59.3 keV 
(    and 67.2 keV (   . The solid black curve shows the final reconstructed incident 
spectrum, correcting for the Doppler broadening of the characteristic peaks.   
Figure 4.2.4 Measured 90
o 
spectrum and reconstructed incident spectrum for the 250 
kVp beam filtered by 0.25 mm Cu. 
 
The reconstructed incident spectrum for each beam was compared to the 
corresponding spectrum from MC simulations and shown in Figures 4.2.5-4.2.7. All of 
the results show reasonable agreement between the two spectra, validating the MC model 
for the Phillips RT-250 orthovoltage machine. Some disagreement is present due to errors 
arising from the complex nature of the measurement and reconstruction procedure. The 
poor energy resolution of the reconstructed spectra and any extra scatter due to the 




Figure 4.2.5 Photon spectrum validation of 250 kVp beam.  





Figure 4.2.7 Photon spectrum validation of 75 kVp beam. 
 
4.3 Experimental Validation of Percent Depth Dose  
In order to further confirm the validity of the MC model of the Phillips RT-250 
orthovoltage machine, PDD data were measured and compared against MC results. PDD 
is one of the key dosimetric quantities closely associated with the radiation quality of a 
radiotherapy beam and utilized as a means to verify the beam energy. Dose distribution 
can be measured using ion chambers, diode detectors or film dosimetry. Film dosimetry 
provides high spatial resolution and therefore is preferred for collecting dose information 
in high dose-gradient regions. Gafchromic EBT films (Ashland Inc., Covington, KY) are 
a type of radiochromic film that has the capability to provide relative and absolute 
dosimetry of radiotherapy beams. Radiochromic films instantly change color when 




The Gafchromic EBT film has low energy dependence [68], near-tissue equivalence  
[69], and a high spatial resolution (< 0.1 mm) [70].  
The film was characterized and calibrated by establishing the dose response curve 
to convert net optical density (netOD) to dose following published methodologies [69, 
71, 72]. For all film dosimetry measurements, films were taken from a single sheet of 
Gafchromic EBT film (lot # 47277-03I). For the calibration procedure 33 pieces    
       were cut from a single sheet of film. The film was exposed to a range of doses 
from 0-7 Gy for the 250 kVp (0.25 mm Cu), three pieces for each dose level. The films 
were placed at a source-to-film distance of 50 cm and placed on top of a thin layer of 
transparent plastic tape, supported by a Styrofoam frame. The beam-output  is determined 
following AAPM TG-61 [73] report which provides a formalism  to calculate the dose at 
the surface of a full phantom using the following equation: 
                     [(
 ̅  
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 (4.4.1)   
where   is the free-in-air chamber reading, corrected for temperature, pressure, ion 
recombination, polarity effect, and electrometer accuracy;    is the air-kerma calibration 
factor for the specific beam quality;    is the backscatter factor that accounts for 
phantom scatter;           is the chamber stem correction factor; and [    ̅̅ ̅̅̅  ⁄     
 ]    is 
the ratio for water-to-air of the mean mass energy absorption coefficient averaged over 
the incident spectrum. Equation (4.4.1) yields the dose to water from a free-in-air 
chamber reading and the Accredited Dosimetry Calibration Laboratory (ADCL) provides 




factor   , the dose in air to a water medium is obtained, and film pieces were exposed in 
air to known doses in a water medium [69].  
The doses delivered to the films ranged from 0.4 to 7.0 Gy for a total of 10 dose 
levels with 3 film pieces for each exposure. The films were scanned approximately 24 
hours after exposure using an Epson Expression 10000XL (Epson America, Inc. Long 
Beach, CA) flat-bed document scanner in transmission mode. The scanned images were 
obtained in 48-bit RGB color mode and saved in tagged image file format (TIFF). A 
cardboard template with a         cut-out was used on the scanner to position each 
film at a reproducible and central location on the scanner while blocking out the rest of 
the scanning area. The images were processed using the public domain imaging 
processing software ImageJ (National Institute of Health, Bethesda, MD) [74] to measure 
the intensity     and standard deviation (  ) for each film as a mean pixel intensity value 
over a centralized region of interest. 
The        value for each independent film exposed to a dose value    is 
defined as [71]: 
                (
            
              
) (4.4.2)   
where       is the film intensity for an unexposed film piece (i.e.       ),       is the 
intensity with zero-light transmission, and          is the film intensity for dose   . The 
average           is calculated as a weighted average of the three individual      
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The dose response curves for all three channels (red, green, and blue) are shown 
in Figure 4.3.1 and show the dose response of each separate channel as a function of dose 
delivered. Figure 4.3.2 shows the sensitivity curve for all three channels. The sensitivity 
curve was calculated by numerically taking the first derivative of the dose response 
curve. It can be observed from both curves that for all the dose levels used in this study, 
the red channel consistently yields the highest values of       as well as sensitivity. At 
dose levels below       the sensitivity is anywhere between 50 – 85 % higher than the 
green channel and around 200 – 300 % higher than the green channel. The red and green 
channel yield similar sensitivities at doses above      and roughly 100 % higher than the 
blue channel. Therefore, the red channel was chosen to process all film dosimetry 
throughout this study. 




Figure 4.3.2 Dose sensitivity curve for the 250 kVp beam for all three color channels. 
 
The PDD was measured using the calibrated EBT film from the same lot (lot # 
47277-03I) cut into rectangular strips of           . The strips were positioned in 
between 6 cm slabs of solid water (Gammex, Inc. Middleton, WI) and irradiated with the 
0.25 mm Cu 250 kVp beam at reference condition (SSD 50 cm,          ). The solid 
water was chosen in order to perform quick measurements of the PDD, while avoiding 
the setup of a liquid water phantom. The films were scanned using the same procedure 
used in the calibration study, using a cardboard cut-out of   20.3 cm to consistently 
place the films on the center of the scanner. A post-processing script was written in 
MATLAB 7.13.0.564 (Mathworks ®, Natick, MA) to apply the dose calibration and 
extract the PDD curve. The PDD curve was measured twice and averaged to obtain the 




 Figure 4.3.3 Percent depth dose validation for 250 kVp beam. MC results are compared 
against film and chamber measurements. 
 
The MC results for the PDD curve of the 250 kVp beam were compared with film 
measurements and the comparison is shown in Figure 4.3.3. The match between the two 
curves was considered acceptable for all depths with a maximum difference between 
PDD values of 4 % at a depth of 2 cm (90.9 % versus 86.9 %) but remained under 2 % 
for most depths. This was considered acceptable given the limitations of the film 
measurement for orthovoltage beams and the use of solid water as opposed to performing 
measurements in a liquid water phantom. These limitations include beam attenuation of 
the orthovoltage beam through the film and solid water material which can lead to 
changes in the dose calibration of the film [72]. Other possible explanations for some of 
the disagreement are uneven surface contact between the film and the solid water. 




this can still affect the measurements. Lastly, any small deviation in alignment can also 
affect the measurements specially when dealing with an orthovoltage beam. 
The MC results and the film measurements for the 250 kVp beam were also 
compared with the ion-chamber-measured PDD data (CC-04, Scandatronix/Wellhofer, 
Schwarzenbruck, Germany) obtained from the machine data book and deduced from 
published literature [72]. The agreement with the ion-chamber measurements was an 
improvement over the film measurement (Figure 4.3.3) with a maximum difference 
between PDD values of 2.1 % (88.8 % versus 90.9 %) at a depth of 2 cm. The 
disagreement between the two curves remained under 1.5 % for all other depths. This 
agreement was acceptable again considering the orthovoltage nature of the beam and the 
volume averaging errors that arise from the ion-chamber measurements. The poor spatial 
resolution of the ion-chamber measurements around the build-up region give rise to 
discrepancies in the PDD curve that do not exist in the MC results.  
The MC PDD curves were also compared with ion-chamber data for the 75 kVp 
and 125 kVp beams and the results are shown in Figures 4.3.4 and 4.3.5. The results 
show close agreement between both curves with some discrepancies similar to those of 
the 250 kVp. The 125 kVp PDD data reached a maximum disagreement of 3 % (73.2 % 
versus 70.2 %) at a depth of 2 cm and remained under 2.5 % for all other depths. The 75 
kVp PDD data reached a maximum disagreement of 2.2 % (86.6 % versus 88.8 %) at a 
depth of 0.5 cm but remained under 1 % for all other depths.  
Overall, the MC PDD results and ion-chamber measurements showed good 
agreement for the whole range of kilo-voltage settings (75 kVp through 250 kVp). This 




Phillips RT-250 orthovoltage machine. The model is able to reproduce the spectral and 
dosimetric characteristics of the beam for any kilo-voltage setting and filtration, and 
allows the freedom to add any custom filter or setup. The model is able to accomplish 
this without the need to model the bremsstrahlung production of x-rays in the machine 
head. This step significantly reduces computation time by at least a couple of orders of 
magnitude, allowing for a flexible and fast simulation of the x-ray machine. 
Improvements in the accuracy of the model can be expected with improved information 




Figure 4.3.4 Percent depth dose validation for 125 kVp beam. MC results are compared 
against film and chamber measurements. 
 
Figure 4.3.5 Percent depth dose validation for 75 kVp beam. MC results are compared 





YTTERBIUM-169 SOURCE EMULATION 
This part of the project is aimed at emulating the dosimetric and spectral 
characteristics of an Yb-169 brachytherapy source using a Phillips RT-250 orthovoltage 
x-ray machine. The fundamental differences between a brachytherapy source and an 
external source of radiation make the development of a perfect replacement for the source 
an unlikely outcome, and not the intended purpose of the study. Thus, this task seeks to 
establish the best available surrogate of the Yb-169 brachytherapy source using the 
orthovoltage x-ray machine, such that it facilitates in-vitro and in-vivo studies of GNRT. 
The gamma-ray spectrum of Yb-169 has an intensity-weighted average energy of just 
92.8 keV, with more than half of the photons with energies between 49 and 63 keV. 
Therefore, the initial goal of the project is to reproduce the region around 49 to 63 keV 
photons via filtration of the RT-250 orthovoltage beam, thereby reproducing the general 
characteristics of the photon spectrum.  
5.1 Photon Spectrum Approximation 
Table 5.1.1 Available beams from the Phillips RT-250 orthovoltage machine. 




250 0.25 mm Cu 





Figure 5.1.1 Photon spectrum and intensity-weighted average energy for all available 
beams from the Phillips RT-250 orthovoltage machine. 
 
The model and methodology described in the previous chapter was used to 
compute the photon spectrum for all available x-ray beams on the Phillips RT-250 x-ray 
machine outlined in Table 5.1.1. The results presented in Figure 5.1.1 show the photon 
spectrum of each beam along with its corresponding intensity-weighted average energy. 
The average energy ranges from 38.5 keV for the 75 kVp beam all the way up to 121 keV 
for the thoraeus-filtered (0.4 mm Sn + 0.25 mm Cu) 250 kVp beam. The copper filtered 
250 kVp beam has an average energy of 89.3 keV, the closest to that of the Yb-169 
gamma-ray spectrum (92.8 keV). This beam would generate the strongest agreement with 
the dosimetric behavior of Yb-169 when compared to all other beam available from the 




characteristic x-rays from the tungsten target at around 59.3 keV (  ) and 67.2 keV (  ), 
higher than the major peaks in the Yb-169 gamma-ray spectrum (Figure 1.1.1). The 
region around these major peaks contains about two-thirds of all photons in the Yb-169 
gamma-ray spectrum and is mostly responsible for the dose enhancement expected from 
the use of an Yb-169 source during GNRT. Therefore, while the copper-filtered 250 kVp 
beam yields a close approximation to the Yb-169 spectrum in terms of the average 
energy, an attempt is made to improve this approximation by reproducing the strong 
spectral lines of the Yb-169 around ~49 and ~63 keV by further filtering the copper-
filtered 250 kVp beam.  
The filtering of any x-ray beam normally results in the hardening of the beam 
with an overall increase in the average energy of the spectrum.  However, many metals 
can affect the properties of the spectrum in many different ways. This is accomplished by 
exploiting the K-edge and subsequent increase in attenuation above certain energies. 
Furthermore, some metals are capable of producing fluorescence photons in the kilo-
voltage region that can be used to produce photons at a specific energy. This technique 
would serve to replace a portion of the attenuated photons in the original x-ray spectrum 
with fluorescence x-rays at a lower energy, effectively tuning the quality of the x-ray 
spectrum. A similar technique is routinely used in mammography imaging studies [75-
77] to filter the high energy portion of a spectrum with the aim of improving contrast and 
reducing the dose to the patient. This method is known as K-edge filtering and it involves 
the use molybdenum (Mo) or rhodium (Rh) to filter out photons above the K-edge of the 
filter material. Molybdenum and rhodium are chosen because the K-edge energies lie 




and 23.2 keV respectively, effectively tuning the photon spectrum to the desired level.  
In the case of the current study, the x-ray spectrum needs to be modified to 
reproduce the strong spectral lines of Yb-169 at around ~50 keV. Following this logic, an 
erbium (Er) foil was chosen as a filter material because it has a K-edge energy of 57.49 
keV which lies just below the characteristic peaks from the tungsten target in the RT-250 
x-ray machine. More importantly, the K-edge fluorescence peaks of Er match the features 
of the Yb-169 gamma-ray spectrum with energies of 49.1 keV (  ) and 55.7 keV (  ). 
Figure 5.1.2 shows the resulting spectrum of the 250 kVp beam filtered by a 0.25 mm 
erbium foil compared to the original 250 kVp beam filtered by just copper.   
 
Figure 5.1.2 Photon spectrum of 250 kVp (Cu) compared to the same beam after the 
addition of a 0.25 mm erbium filter. The strong characteristic lines of tungsten on the 





Figure 5.1.3 Photon spectrum of 250 kVp (Cu) after the addition of a 0.25 mm erbium 
filter compared to the photon spectra of Yb-169. The fluorescence photons from erbium 
at 49.1 keV and 55.7 keV match the strongest part of the Yb-169 spectrum. 
 
Figure 5.1.3 compares the resulting spectrum with that of Yb-169 and illustrating 
the improved agreement in the desired region. The photon spectrum of the Er-filtered 250 
kVp was measured using the 90
o
 Compton scattering technique described in the previous 
chapter. A                  Er foil (Sigma-Aldrich, St. Loius, MO) was placed 
along the beam path below the square lead (Pb) collimators on the machine head. The 
field size was set to           at 50 cm SSD. The measured spectrum is shown in 
Figure 5.1.4 and is compared to the MC results. The results closely match each other 




above. It should be noted that the measured spectrum lacks the necessary energy 
resolution to appropriately measure the fluorescence peaks of Er. This is a consequence 
of the Doppler broadening described in section 4.2 and the increased requirements on 
energy resolution placed by the deconvolution procedure defined by equation 4.3.6. The 
deconvolution procedure needs appropriate resolution around each characteristic peak in 
order to correctly deconvolve the spectrum and correct for the Doppler broadening on the 
carbon scatterer. Nonetheless, the agreement between the MC results and the measured 
spectrum is deemed acceptable considering the limitations of the technique.  
Figure 5.1.4 Photon spectrum of the Er-filtered 250 kVp calculated by MC results 
compared to measured results reconstructed from 90
o




5.2 Percent Depth Dose Comparison 
Figure 5.2.1 Percent depth dose comparison for all available beams from the Phillips RT-
250 machine as well as a hypothetical Yb-169. 
 
The PDD data for all available x-ray beams from the Phillips RT-250 
orthovoltage machine were calculated using the MC model described in the previous 
chapter. In addition to the available beams, a hypothetical Yb-169 beam was created by 
replacing the photon point source of the orthovoltage machine with the photon spectrum 
of Yb-169. This beam was created in an attempt to investigate how the dosimetric 
characteristics of an Yb-169 brachytherapy source would compare to the available 
orthovoltage beams. Figure 5.2.1 shows the resulting PDD data for available beams along 




of Cu showed remarkable agreement with the PDD curve of the hypothetical Yb-169 
beam. This curve was also compared to the Er-filtered beam developed in section 5.1 and 
the results are shown in Figure 5.2.2. The results demonstrate that the addition of the Er 
filter modifies the photon spectrum of the orthovoltage machine without severely 
affecting the PDD curve of the 250 kVp Cu-filtered beam. Therefore, the modified beam 
is a better match to the Yb-169 source in terms of photon spectrum while still being able 
to emulate the PDD data of the Yb-169 source as demonstrated in Figure 5.2.2. 
 
 
Figure 5.2.2 Percent depth dose data for the Cu-filtered 250 kVp beam and the Er-




5.3 Secondary Electron Spectra 
In order to further evaluate if the filtered photon spectrum would more closely 
match the dosimetric characteristics of the bare Yb-169 spectrum during GNRT, the 
secondary electron spectrum for each beam is also compared. The condensed history 
Monte Carlo (MC) code EGSnrc [48] and user code DOSXYZnrc [49] were used to 
calculate the secondary electron spectrum for each one of the beams. The EGSnrc code 
was used for this task because the source code is immediately available for modification 
using the techniques described in section 2.6. The electron spectra were collected using 
logarithmically spaced bins covering a minimum energy of 0.025 keV up to the 
maximum energy of each spectrum with a minimum bin width of 25 eV. 
The methodology was used to compute the secondary electron spectra of a 1x1x1 
cm
3
 tumor on top of a 30x30x29 cm
3
 phantom at 50 cm SSD. The source option used was 
that of a collimated rectangular beam from a point source with the photon spectrum 
defined as that obtained from the MCNP model. The material composition of the tumor 
and phantom was taken as four-component ICRU tissue (i.e. 10.1 % hydrogen, 11.1 % 
carbon, 2.6 % nitrogen and 76.2 % oxygen). The tumor was loaded with 7 mg of gold per 
g of tissue (0.7 % by weight) and the density appropriately increased to 1.007 g/cm
3
.  The 
spectrum was computed for the Cu and thoraeus-filtered 250 kVp beam, the Er-filtered 
beam and the hypothetical Yb-169 beam. The resulting photoelectron spectra shown in 
Figure 5.3.1 demonstrate the basic disparities between the spectra. The resulting electron 
spectra show the total number electrons originating from photoelectric absorption 
interactions for each beam (Electrons from atomic relaxation and Auger electron 




Figure 5.3.1 Spectra of photoelectrons released in the tumor region for each photon 
beam. The figure shows the spectrum from gold and tissue for the tumor loaded with 7 
mg Au/g tissue. 
 
Table 5.3.1 Total yield of photoelectrons (PE) and Auger/Coster-Kronig electrons (AE) 
and intensity-weighted total energy from gold and tissue for a tumor loaded with 7 mg 
Au/g of tissue for each separate beam. Auger/Coster-Kronig electrons are only produced 
in gold. All values listed in the table are normalized per source photon. 
 





















Yb-169 0.0142 0.618 0.00930 0.365 0.983 0.0264 0.0983 
250 kVp Cu 0.0139 0.564 0.00790 0.299 0.863 0.0257 0.101 
250 kVp Cu+Er 0.0152 0.603 0.00964 0.334 0.937 0.0282 0.110 





The results presented in Figure 5.3.1 show the differences that arise in the 
photoelectron spectrum from the choice of each different beam. The thoraeus-filtered 
beam shows the largest disagreement with the Yb-169 source, as it fails to reproduce any 
of the strong spectral lines present in the photoelectron spectrum from the Yb-169 source. 
The Cu-filtered beam shows a much better agreement, corroborating the PDD and photon 
spectrum analysis as shown before. However, the Er-filtered beam manages to reproduce 
some of the strong spectral lines present in the Yb-169 spectrum around 50 keV, and 
show a much better agreement with the Yb-169 source. The Er-filtered secondary 
electron spectrum shows decreased photoelectron yield around ~57 keV due to the K-
edge of Er and a sharp increase in the photoelectron yield around 50 keV due to the 
fluorescence photons, improving the matching with the Yb-169 spectrum. 
Table 5.3.1 shows a quantitative assessment of the secondary electron spectrum 
for each one of the beams. The table lists the total photoelectron and Auger/Coster-
Kronig electrons per source photon from gold and tissue separately, as well as the total 
energy from such electrons per source photon. This type of analysis gives insight into 
exactly how each beam locally deposits energy and how close the correlation is between 
each one of the x-ray beams and the Yb-169 source. The results show the Yb-169 beam 
with the highest total energy deposition of 1.08 keV per source photon. The thoraeus-
filtered beam was in the largest disagreement depositing only 0.690 keV per source 
photon. This is stark difference between the two with a reduction of about 36 % in total 
energy transferred to electrons in the tumor region per source photons. The Cu-filtered 
beam showed much closer agreement with 0.964 keV deposited per source photon, but 




showed the best agreement with the Yb-169 with a total of 1.05 keV deposited per source 
photon and just 2.7 % lower than the Yb-169 source. 
5.4 Discussion 
The best surrogate available for the Yb-169 source has been established as a 0.25 
mm Er-filtered 250 kVp beam from the Phillips RT-250 orthovoltage machine. At a 
glance, the original Cu-filtered 250 kVp beam from the Phillips RT-250 machine may 
appear to be a good replacement with an intensity-weighted average energy of 89.3 keV, 
very close to the 92.8 keV of the Yb-169 source. An examination of the PDD data for 
each beam confirms remarkable agreement between the two and the best match out of all 
the standard beams from the Phillips RT-250 machine. However, a close approximation 
in PDD alone is insufficient to properly emulate the dosimetric characteristics of the Yb-
169 source for in-vivo and in-vitro studies. As shown in this study, the incident photon 
spectrum plays a far more important role in reproducing the local energy deposition 
pattern of the Yb-169 source. Thus, a K-edge filtering and fluorescence production 
technique adopting an Er filter was used in this investigation to reproduce some of the 
gamma-ray lines of the Yb-169 spectrum. The presented results demonstrate a strong 
qualitative agreement between the spectra in the desired low energy region around 50 
keV. The PDD data for this modified beam demonstrate that the addition of the Er filter 
does not dramatically affect the PDD of the original beam and, still closely matching the 
PDD between the two beams. 
The analysis of the secondary electron spectrum for each one of the beams 




characteristics of the Yb-169 source. This type of analysis provides a better perspective 
for the local energy deposition pattern due to each source during GNRT, and serves as an 
effective tool to gauge which beam would work as the best surrogate. The results clearly 
demonstrate that the improved correlation between the initial photon spectra directly 








The research presented herein is based on various investigations aimed at the 
design and pre-clinical study of an Yb-169 brachytherapy source within the context of 
GNRT. The source design must meet the practical constraints for producing a 
brachytherapy source that is appropriate for clinical translation, while simultaneously 
being optimized for GNRT. The first task involves the encapsulation design of the Yb-
169 source to ensure that the low-energy portion of the photon spectrum is preserved for 
maximal dose enhancement. The study focused on a total of four encapsulation designs of 
various materials and configurations, and the effects of these designs on the dose 
enhancement and radiosensitization during GNRT were scrutinized via MC models.  
The MC results reflect the importance of careful consideration of the source 
design for a brachytherapy application of GNRT. The change in the photon spectrum 
through the encapsulation of the source affects the dose enhancement not only 
macroscopically but also microscopically on a cellular scale. The changes in the photon 
spectrum directly translate to changes in the photoelectron yield and consequently, to 
changes in the local energy deposition during GNRT. The results of this study 
consistently show the titanium encapsulation design to have favorable properties in terms 
of further improving dose enhancement and radiosensitization effects during GNRT. 
Titanium is a low-weight, high-strength material with the necessary structural integrity 
and biocompatibility to encapsulate the radioactive core of an HDR Yb-169 




while allowing minimal loss of photons, and more specifically, low-energy photons, 
through the capsule. Furthermore, the increased strength of titanium might provide the 
opportunity to further decrease the thickness of the capsule, thereby improving the dose 
enhancement characteristics of the source.   
The second task of the research consists of the characterization of the optimized 
brachytherapy source via MC techniques by computing the AAPM TG-43 dosimetric 
parameters: anisotropy function, radial dose function, air kerma strength, and dose rate 
constant. The characterization was performed for the titanium encapsulation design, 
which was deemed an ideal candidate for an HDR brachytherapy source for GNRT, and 
compared with a more conventional stainless steel design. The 2D anisotropy function for 
the stainless steel source design reflects increased dose perturbations due to higher 
attenuation through the stainless steel as opposed to titanium. The reduced attenuation 
through the titanium encapsulation also improves the strength of the source by 10 % 
when compared to the stainless steel design.  
The third task involves the development and validation of an MC model of the 
Phillips RT-250 orthovoltage x-ray machine. The MC results were corroborated with 
measured photon spectra and PDD data, validating the MC model that was developed. 
The validated MC model of the Phillips RT-250 machine was used in the development of 
an external x-ray beam that would emulate the dosimetric characteristics of the Yb-169 
brachytherapy source during GNRT. The most appropriate surrogate of the Yb-169 
brachytherapy source was established as an Er-filtered 250 kVp beam from the Phillips 
RT-250 machine. The Er-filtered 250 kVp beam directly translated to improved 




The adopted approach ensures improved emulation of the local energy deposition 
characteristics of Yb-169, and was the best surrogate for the Yb-169 brachytherapy 
source among the beams investigated in this study.  
In conclusion, the major goals outlined in the introduction of this dissertation 
were accomplished. The encapsulation design for an Yb-169 brachytherapy source was 
optimized for GNRT. An external beam surrogate of the Yb-169 source was developed to 
facilitate in-vitro and in-vivo studies of GNRT. There are several future tasks that 
naturally arise from the results of the current work. The first is the in-vitro/in-vivo study 
to test the effectiveness of GNRT with an Yb-169 source using the source emulation 
techniques described herein. The second task is the production of a titanium-encapsulated 
Yb-169 brachytherapy source as specified by the design described in Chapter 2. 
Specifically, the manufacturing procedures and appropriate welding techniques that are 
necessary for a titanium encapsulated source need to be investigated. The third task is the 
characterization of the produced Yb-169 source for clinical brachytherapy dosimetry 
following the AAPM TG-43 report. The last task is the corroboration of the expected 






PHOTOELECTRON SPECTRA  
Figure A.1 Spectrum of photoelectrons released in the tumor region for the aluminum 
encapsulation design. The figure shows the spectrum from gold and tissue for the tumor 
loaded with 7 mg Au/g tissue and from tissue case. 
Figure A.2 Spectrum of photoelectrons released in the tumor region for the aluminum 




Figure A.3 Spectrum of photoelectrons released in the tumor region for the all 
encapsulation designs. The figure shows the spectra from gold and tissue for the tumor 
loaded with 7 mg Au/g tissue and from tissue only from 0.025 keV up to 100 keV. The 
pattern of photoelectrons for each source design is very similar with some differences 
noticed in the region below 100 keV. The aluminum, aluminum/titanium and titanium 
designs consistently show improved photoelectron yield throughout this region when 





RECONSTRUCTED INCIDENT SPECTRA OF PHILLIPS RT-250 
ORTHOVOLTAGE MACHINE 
Figure B.1 Measured 90
o 
spectrum and reconstructed incident spectrum for the 75 kVp. 
Figure B.2 Measured 90
o 





Figure B.3 Measured 90
o 
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